Anne Andrews Group
­­­­­
Invited Talks

1997  |  1998  |  1999  |  2000
2001  |  2002  |  2003  |  2004
2005  |  2006  |  2007  |  2008
2009  |  2010  |  2011  |  2012
2013  |  2014  |  2015  |  2016  2017  | 

­

Contributed Presentations

1992  |  1993  |  1995  |  1996
1997  |  1998  |  1999  |  2000
2001  |  ­2002  |  2003  |  2004
2005  |  2006  |  2007  |  2008
2009  |  2010  |  2011  |  2012
2013  |  2014  |  2015  |  2016  2017 

Talks/Presentations ­ ­ ­ ­ ­

­ ­ ­

Invited Talks

1997  |  1998  |  1999  |  2000  |  2001  |  2002  |  2003  |  2004  |  2005  |  2006  |  2007  |  2008  |  2009  |  2010  |  2011  |  2012  |  2013  |  2014­  |  2015 |  2016­  |  2017 | 

2017 ­

top­

169.TBD. 9th International Conference of the Africa Materials Research Society Meeting, Gaborone, Botswana(December 11-14, 2017).

168.TBD. Genetic, Physiologic, and Therapeutic Perspectives on Transporters in the Nervous System, International Society for Neurochemistry Satellite Meeting, Maintenon, France (August 25-29, 2017).

167.TBD. International Conference on Chemical Bonding, Kauai, HI (June 22-26, 2017).

166.TBD. University of California, Davis, Davis, CA (April 6, 2017).

165. Aptamer field-effect transistors as neurochemical sensors to monitor neurotransmitters in vivo. 253rd National Meeting of the American Chemical Society, San Francisco, CA (April 2, 2017).

164. Self-assembly in confined spaces: Using defects to advantage. 253rd National Meeting of the American Chemical Society, San Francisco, CA (April 2, 2017).

163. The brain is more than a computer. ACS Board Meeting, 253rd National Meeting of the American Chemical Society, San Francisco, CA (April 2, 2017).

162. TBD. One Chemistry Symposium, Johns Hopkins University, Baltimore, MD (March 26-29, 2017).

161. 5-HT1A autoreceptor control of serotonin signaling—Rethinking modes of inhibitory feedback. Pittsburgh Conference on Analytical Chemistry and Applied Spectroscopy,, Chicago, IL (March 8, 2017).

160. Functional nanomaterials and chemical neurotransmission. Gordon Research Conference on GPCRs,, Lucca, Italy (March 13, 2017).

2016 ­

top­

159. Functional nanomaterials and chemical neurotransmission. Self-Assembly in Confined Spaces Workshop, CIC biomaGUNE, San Sebastian, Spain (October 27, 2016).

158. Grand challenges in understanding the brain: Integrating models, technologies, and scale. Measuring the Brain, National Science Foundation Workshop, Arlington, VA (October 12, 2016).

157. In vivo electronic neurotransmitter sensing. Kavli Symposium on Chemical Neurotransmission: What Are We Thinking? 252th National Meeting of the American Chemical Society, Philadelphia, PA (August 22, 2016).

156. How can we know who will benefit from SSRIs? International Society for Serotonin Research Meeting, Seattle, WA (July 25, 2016).

155. Chemical neurotransmission and functional nanomaterials. Lawrence Livermore National Laboratory, University of California, Berkeley, Berkeley, CA (June 14, 2016).

154. The future of monitoring serotonin in vivo. Plenary lecture for Monitoring Molecules in Neuroscience: 16th International Conference, Gothenburg, Sweden (May 29-June 2, 2016).

153. The future of monitoring serotonin in vivo. Center for Mind, Brain and Computation, Stanford University, Palo Alto, CA (May 9, 2016).

152. The future of monitoring serotonin in vivo. Plenary Lecture for the Neuroengineering Workshop, McGill University, Montreal, Quebec, Canada (May 5, 2016)

151. TBD. UCLA Neuroscience Integrative Center on Addiction, University of California, Los Angeles (April 7, 2016).

150. Chemical neurotransmission and functional nanomaterials. NaNaX 7, Philipps University , Marburg, Germany (April 8, 2016).

149. Chemical neurotransmission and functional nanomaterials. Student Hosted Colloquia Series, Chemistry Department, Stanford University (March 7, 2016).

2015 ­

top­

148. Decoding serotonin neurotransmission. Department of Pharmacology, University of Texas Health Science Center, San Antonio, TX (December 2, 2015).

147. How can we know who will benefit from antidepressants? Neuroscience Center, University of Helsinki, Helsinki, Finland (October 26, 2015).

146. Chemical neurotransmission and functional nano materials. Nanoscience Days Conference, University of Jyväskylä, Jyväskylä Finland (October 22-23, 2015).

145. How can we know who will benefit from SSRIs? Department of Pharmacology, University of Michigan, Ann Arbor, MI (October 14, 2015).

144. Micro- to nanoscale neurotransmitter sensors. Columbia NeuroTechnology Center Kavli Futures Symposium, Columbia University, New York, NY (September 25-26, 2015).

143. Nanoengineered substrates for nucleic acid biorecognition. 6th International Conference on Nanoscience and Technology, Beijing, China (September 4, 2015).

142. Nanoengineered substrates for nucleic acid biorecognition. Institute of Functional micro- to nanoscale materials for neurotransmitter sensing, Soochow University, Suzhou, China (August 29, 2015).

141. Improving in vivo neurotransmitter sensors. 250th National Meeting of the American Chemical Society, Boston, MA (August 17, 2015).

140. Micro- to nanoscale neurotransmitter sensors. Micro- and Nanotechnologies Workshop, Brigham and Women’s Hospital, Boston, MA (July 30, 2015).

139. Serotonin encoding of emotionally important information. Harvard Medical School, Boston, MA (July 29, 2015).

138. Serotonin in early development: Maternal stress and prenatal exposure to selective serotonin reuptake inhibitors. UCSB Summer Institute in Cognitive Neuroscience: Cognitive Neuroscience of Development, University of California, Santa Barbara, CA (July 1, 2015).

137. Micro- to nanoscale neurotransmitter sensors. Kavli Futures Symposium, Emerging Technologies for Neuroscience: Building the New Brain Science, University of California, Santa Barbara, CA (June 27-28, 2015).

136. Serotonin encoding of emotionally important information. 2015 Annual Hatos Center Board Meeting, UUniversity of California, Los Angeles, CA (April 22, 2015).

135. How can we know who will benefit from antidepressants? 3rd Annual Cell Biology Symposium, California Lutheran University, Thousand Oaks, CA (April 19, 2015).

134. Enabling biomolecule selection by small molecule-functionalized substrates: A decade of collaborative progress. 249th Meeting of the American Chemical Society, Denver, CO (March 24, 2015).

133. Decoding serotonin transmission. The Pittsburgh Conference on Analytical Chemistry and Applied Spectroscopy, New Orleans, LA (March 8-12, 2015).

132. Decoding serotonin neurotransmission. Analytical Chemistry Seminar Series, University of California, Riverside, Riverside, CA (February 19, 2015)

131. Decoding chemical neurotransmission. Lilly Endowment Analytical Sciences Seminar Series, University of Notre Dame, Notre Dame, IN (February, 12, 2015).

2014 ­

top­

130. Decoding serotonin transmission. 2nd International Symposium on the Functionality of Organized Nanostructures (FON'14), Tokyo, Japan (November 27, 2014).

129. Decoding serotonin transmission. Kavli Institute for Brain and Mind, University of California, San Diego, CA (October 21, 2014).

128. Developing nanoscale measurements for the brain. Science at the Edge Lecture Series ,, Michigan State University, East Lansing, MI (October 17, 2014).

127. Predicting antidepressant response. Neuroscience Program, Michigan State University, East Lansing, MI (October 16, 2014).

126. Decoding serotonin transmission. University of Maryland School of Medicine, Baltimore, MD (October 14, 2014).

125. Decoding serotonin transmission. Department of Chemistry, Georgia Institute of Technology, Atlanta, GA (September 22, 2014).

124. Why faster is better for serotonin monitoring: An update. 15th International Monitoring Molecules in Neuroscience Conference, University of California, Los Angeles, CA (August 4, 2014).

123. Serotonin and dopamine release and reuptake by fast microdialysis. 11th International Society for Serotonin Research Meeting, Cape Town, South Africa (July 12, 2014).

122. Molecular recognition of neurotransmitters to advance in vivo nanobiosensing. 6th International Symposium on Bioanalysis, Biomedical Engineering and Nanotechnology, Hunan University, Changsha, China (May 30, 2014).

121. Serotonin in depression & anxiety: From translational medicine to a chemical connectome. Center for Addiction Research, Department of Pharmacology and Toxicology, University of Texas Medical Branch, Galveston, TX (March 21, 2014).

120. Chemical brain mapping. El Camino College, Los Angeles, CA (February 28, 2013).

119. Predicting antidepressant response. Molecular Biology Institute Annual Retreat, University of California, Los Angeles, CA (January 25-26, 2014).

118. Chemical brain mapping. Department of Chemistry, California State University Los Angeles, Los Angeles, CA (January 1, 2014).

2013

top­

117. Serotonin in depression & anxiety: From translational medicine to a chemical connectome. Department of Chemistry, University of Minnesota, Minneapolis, MN (October 29, 2013).

116. SERT gene variants: A complex case for involvement in mood disorders and their treatment. Zilkha Neurogenetics Institute, Keck School of Medicine, University of Southern California, Los Angeles, CA (September 18, 2013).

115. Serotonin in depression & anxiety: From translational medicine to a chemical connectome. Chemistry & Biology Interface Day, University of California, Los Angeles, CA (September 5, 2013).

114. Serotonin in depression & anxiety: From translational medicine to a chemical connectome. Joint Research Institute, Beijing, China (July 1, 2013).

113. Brain mapping. Three Pillars, One University, University of California, Los Angeles, CA (April 23, 2013)   

112. Toward a chemical connectome. Leonardo Art Science Rendezvous, Speaking Your Mind, UCLA Art | Sci Center, Los Angeles, CA (April 18, 2013) 

111. Brain biosensing: From micro to nano. Florida International University, Miami, FL (February 14, 2013)

2012

top­

110.  Serotonin in depression & anxiety: From translational medicine to a chemical connectome. 2012 Smalley Institute /Rice Centennial Lecture Series, Rice University, Houston, TX (November 12, 2012).

109. Serotonin in anxiety and mood: New insights based on biosensing. University of California, Los Angeles Semel Institute Psychiatry Grand Rounds, Los Angeles, CA (October 30, 2012).

108.  The neurochip: A functional nanomaterial for multiplexed biorecognition. California NanoSystems Institute/Taiwan National Program on Nanotechnology Joint Workshop, National Tsing Hua University, Hsinchu, Taiwan (October 3, 2012).

107. Imaging neurotransmitter-functionalized nanomaterials: Toward nanobiosensing. Monitoring Molecules in Neuroscience, 14th International Conference, London, England (September 19, 2012).

106.  Monitoring serotonin: Why faster is better. Monitoring Molecules in Neuroscience, 14th International Conference, London, England (September 17, 2012).

105.  Serotonin in anxiety and depression: From genetics to nanobiosensing. Jilin University, Changchun, China (June 13, 2012).

104.  Serotonin in anxiety and depression: Genetics and predicting treatment response. Harbin Institute of Technology, Harbin, China (June 12, 2012).

103.  The neurochip: Functional nanomaterials for multiplexed biorecognition. 5th International Symposium on Bioanalysis, Biomedical Engineering and Nanotechnology (ISBBN 2012), Hunan University, Changsha, China (June 9, 2012).

102.  Brain biosensing: From micro to nano. Biomedical Engineering Program, University of California, Los Angeles, CA (May 17, 2012).

101. Desperately seeking serotonin: Mood and anxiety disorders and their treatment. Center of Excellence for Neurosciences, Texas Tech University Health Sciences Center, El Paso, TX (April 23, 2012).

100. Serotonin transporter function in peripheral blood cells as a predictor of SSRI responsiveness in the treatment of major depressive disorder. Wayne State University School of Medicine, Detroit, MI (April 4, 2012).

99. Brain biosensing: From micro to nano. Department of Chemistry, Wayne State University, Detroit, MI (April 3, 2012).

2011

top

98. In search of brain biosensors. Indiana University, Department of Chemistry, Bloomington, IL (October 25, 2011). 

97. Multiplexed capture of biological targets. Panel session on Nanobiotechnology & Nanomedicine, ChinaNANO2011 Meeting, Beijing, China (September 7-9, 2011).

96. Nanoengineered materials for biosensor design. Nanoelectronic Devices for Defense & Security Conference, New York University Polytechnic, Brooklyn NY (August 29-September 1, 2011).

95. Brain biosensing: From micro to nano. Department of Bioengineering, University of Washington, Seattle, WA (May 9, 2011).

94. Biomarkers for depression. School of Natural Sciences, University of California, Merced, CA (April 29, 2011).

93. Brain biosensing: From micro to nano. Department of Chemistry, Ben-Gurion University of the Negev (January 19, 2011).

92. Brain biosensing: From micro to nano. Department of Organic Chemistry, The Weizmann Institute (January 18, 2011).

2010

top

91. Micro- to nanoscales for brain biosensing: Desperately seeking serotonin. School of Pharmacy and Biomolecular Sciences, University of Brighton, Brighton, UK (September 17, 2010).

90. Molecular and behavioral influences of the serotonin transporter and its gene variants: Focus on anxiety. Institute of Psychology, Chinese Academy of Sciences (August 24, 2010). 

89. In search of brain nanobiosensors: Neurotransmitter nanoarchitectures and biomolecule recognition. Distinguished Lecture: Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, Institute of High Energy Physics, Chinese Academy of Sciences (August 23, 2010). 

88.In search of brain nanobiosensors: Neurotransmitter nanoarchitectures and biomolecule recognition. IEEE NANO 2010 - Joint Symposium with NANO Korea 2010, Seoul, Korea (August 19, 2010).

87. Effects of serotonin transporter deficiency on extracellular serotonin and other neurotransmitters following MDMA and serotonin-related toxicity models. XXVII Congress of the CINP (Collegium Internationale Neuropsychopharmacologicum), Hong Kong (June 9, 2010). 

2009

top

86. Serotonin and the misbehaving brain. Department of Chemistry, University of Gothenburg, Gothenburg, Sweden (November 6, 2009).

85. Moving from micro - to nanoscales for brain biosensing: Small molecule recognition as a critical first step. International Institute for Nanotechnology 2009 Symposium, Northwestern University, Evanston, IL (October 29, 2009).­ 

84. Molecular ­and behavioral influences of the serotonin transporter and its gene variants, School of Biological Sciences, Fudan University, Shanghai, China (September 4, 2009). 

83. Brain Probes: From micro to nano. Cross-Disciplinary Scholars in Science and Technology (CSST) Program, California NanoSystems Institute, University of California, Los Angeles, Los Angeles, CA (August 10, 2009).­ 

82. In search of brain nanobiosensors: Small molecule recognition and biomolecule capture as important first steps. Department of Chemistry, Universidad de Los Andes, Merida, Venezuela (May 22, 2009). 

81. In search of brain nanobiosensors: Small molecule recognition and biomolecule capture as critical first steps. 237th ACS National Meeting & Exposition, Salt Lake City, UT (March 22, 2009). 

80. Faster sampling & insights into adaptive responses in serotonin signaling. 60th Pittsburgh Conference on Analytical Chemistry and Applied Spectroscopy, Chicago, IL (March 11, 2009).

2008

top

79. In vivo approaches to investigating serotonin neurochemistry: From micro- to nanoscales. Chemistry Colloquium, Lycoming College, Lycoming, PA (October 17, 2008).

78.  Interpreting neurotransmitter release in light of altered baseline levels. 12th International Conference on In Vivo Methods, Vancouver, British Columbia, Canada (August 13, 2008).

77. From genes to drugs: SERT-mediated regulation of BDNF, neurogenesis and anxiety. Serotonin Club Meeting, Oxford, England (July 17-19, 2008). 

76. Genetic and environmental predispositions to anxiety: Serotonin transporter and stress. Brain Research Institute, University of California Los Angeles, CA (May 12, 2008).

75. New agonies over Ecstasy: Serotonin and psychostimulants. 59th Pittsburgh Conference on Analytical Chemistry and Applied Spectroscopy, New Orleans, LA (March 6, 2008). 

74. In search of brain nanobiosensors: Small molecule recognition as an important first step. 59th Pittsburgh Conference on Analytical Chemistry and Applied Spectroscopy, New Orleans, LA (March 6, 2008).

73. Frightening complexity of the genetics of anxiety. Genetics Colloquium, Intercollege Program in Genetics, Pennsylvania State University, University Park, PA (February 15, 2008). 

72. Serotonin neurochemistry and the origins of anxiety. Department of Chemistry, Vanderbilt University, Nashville, TN (February 4, 2008).

2007

top

71. Serotonin transporter: A genetic predisposition to a lifetime of anxiety. Department of Chemistry, University of Pittsburgh, Pittsburgh, PA (November 26, 2007).

70. Why I became a scientist! Expanding Your Horizons Conference for 6th-8th grade girls, Women in Science and Engineering Program, Pennsylvania State University, University Park, PA (November 19, 2007).

69. Influence of serotonin transporter gene variants on uptake and anxiety. Department of Chemistry, Vanderbilt University, Nashville, TN (October 30, 2007). 

68. Genetic predisposition to a lifetime of anxiety: The serotonin transporter and brain-derived neurotrophic factor. School of Behavioral and Brain Sciences, University of Texas at Dallas, Dallas, TX (October 8, 2007). 

67. Serotonin neurochemistry and the misbehaving brain. Hanyang University, Seoul, South Korea, June 18, 2007. 

66. In search of brain nanobiosensors: Small molecule recognition as an important first step. 2007 International Conference on Scanning Probe Microscopies, Cantilever-Based Sensors, Nanostructures, Biosensors and Biochips, Jeju Island, South Korea (June 14, 2007). 

65. The neurochip: An advanced nanomaterial for the development of novel biosensors and functionally-directed proteomics. Engineering Conferences International Conference on Nanoscience & Nanotechnology for Biological/Biomedical/Chemical Sensing, Hong Kong (June 6, 2007). 

64. Genetic predisposition to a lifetime of anxiety: The serotonin transporter and brain-derived neurotrophic factor. Department of Psychiatry, University of Pittsburgh, Pittsburgh, PA (May 14, 2007). 

63. The neurochip: An advanced nanomaterial for the development of novel biosensors and functionally directed proteomics. 58th Pittsburgh Conference on Analytical Chemistry and Applied Spectroscopy, Chicago, IL (February 28, 2007). 

62. Serotonin and the misbehaving brain: Unraveling the biology of anxiety and depression. Pennsylvania State University Lectures on the Frontiers of Science, University Park, PA (February 10, 2007). 

61. Developing nanobiosensors for neurotransmitters: Assembly, patterning and application of optimally diluted biospecific capture surfaces. Mesilla Chemistry Workshop on Electron Transfer and Molecular Devices, Mesilla, NM (February 7, 2007).

2006

top

60. The unusual effects of MDMA and methamphetamine in mice with reduced serotonin transporter expression. Department of Pharmacology, University of Texas Health Science Center at San Antonio, San Antonio, TX (November 15, 2006).

59. The serotonin system as a potential therapeutic target in the treatment of early Alzheimer's disease. Department of Pharmacology, Penn State College of Medicine, Hershey, PA (October 9, 2006). 

58. The neurochip: An advanced nanomaterial for the development of novel biosensors and functionally-directed proteomics. Department of Chemistry, University of Wisconsin, Madison, WI (September 28, 2006). 

57. Nanoscale study of heterogeneous brain architectures: Understanding disease mechanisms and devising novel therapeutics. 23rd National Meeting of the American Chemical Society Meeting, San Francisco, CA (September 10, 2006). 

56. The neurochip: Nanostructured neurotransmitter derivatized surfaces for biosensor development. Department of Chemistry, University of California at Davis, Davis, CA (September 8, 2006).

55. Serotonin and the aging brain. Department of Neuroscience, Bordeaux 2 University, Bordeaux, France (July 25, 2006). 

54. MDMA-induced serotonin and dopamine release does not stimulate locomotor activity in SERT knockout mice: Importance of 5-HT1B receptors. Monitoring Molecules in Neuroscience, 11th International Conference on In Vivo Methods, Sardinia, Italy (May 21, 2006). 

53. Serotonin uptake measured by chronoamperometry yields new insights into transporter function. National Institute of Mental Health, Bethesda, MD (February 22, 2006). 

52. The neurochip: Nanostructured neurotransmitter derivatized surfaces for biosensor development. The Houston Society for Engineering in Medicine and Biology Annual Meeting, Houston, TX (February 10, 2006).

2005

top

51. Serotonin and the misbehaving brain. Department of Biochemistry, Trinity College, Dublin, Ireland (December 9, 2005).

50. Serotonin degeneration in Alzheimer’s disease. Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA (May 24, 2005). 

49. The neurochip: An advanced nanomaterial for the development of novel biosensors and functionally-directed proteomics. Foundations of Nanoscience Meeting, Snowbird, UT (April 25, 2005). 

48. Neurotransmitter chip for biosensor design and functionally-directed proteomics. Department of Chemistry, Tokyo Metropolitan University, Tokyo, Japan (March 22, 2005). 

47. Serotonin in the aging brain: Can SRI’s be used to delay neurodegeneration? 2005 Analytical Grantee Symposium, Analytical Partnerships: Transforming Concepts into Medicines, Eli Lilly & Company, Indianapolis, IN (February 22, 2005). 

46. Monoamine uptake revisited using carbon fiber microelectrodes and chronoamperometry. 37th Annual Winter Conference on Brain Research, Breckenridge, CO (January 22, 2005). 

2004

top

45. Serotonin and the misbehaving brain. Chemistry Department Colloquium, The Pennsylvania State University, University Park, PA (November 4, 2004).

44. The neurochip: An advanced nanomaterial for the development of novel biosensors and functionally-directed proteomics. CrossOver 2004, Pennsylvania State University, University Park, PA (October 21, 2004). 

43. Serotonin degeneration and Alzheimer’s disease. Department of Chemistry, Trinity University, San Antonio, TX (September 30, 2004). 

42. Serotonin and the misbehaving brain. Department of Chemistry, Muhlenberg College, Allentown, PA (May 4, 2004). 

41. Serotonin, reward and drugs of abuse. Department of Chemistry, University of Michigan, Ann Arbor, MI (February 19, 2004). 

40. The effects of reduced serotonin transporter expression on neurotransmission, plasticity and behavior. National Center for Biological Sciences, TATA Institute, Bangalore, India (January 3, 2004). 

2003

top

39. The relationship between serotonin and BDNF as trophic factors. 33rd Annual Meeting of the Society for Neuroscience, New Orleans, LA (November 11, 2003).

38. Serotonin and the misbehaving brain: Using analytical chemistry to meet biologic challenges. Department of Chemistry, University of Illinois Urbana Champagne, Urbana, IL (October 24, 2003). 

37. Novel tools for the dynamic analysis of brain chemistry. Midwest Union of Analytical Chemistry Committee Meeting, Indiana University Purdue University Indianapolis, Indianapolis, IN (October, 10, 2003). 

36. SERT as a key regulator of brain-derived neurotrophic factor expression. Monitoring Molecules in Neuroscience: 10th International Conference on In Vivo Methods, Stockholm, Sweden (June 25, 2003). 

35. SERT as a key regulator of serotonergic signaling and the effects on anxiety-related behavior. Monitoring Molecules in Neuroscience: 10th International Conference on In Vivo Methods, Stockholm, Sweden (June 25, 2003). 

34. Serotonin and the fountain of youth: The chemistry of the aging brain. Department of Chemistry, Ohio State University, Columbus, OH (April 8, 2003). 

33. Serotonin and the misbehaving brain. Department of Chemistry, St. Joseph’s University, Philadelphia, PA (April 2, 2003). 

32. Electroanalytical methodology elucidates changes in serotonin and dopamine neurotransmission in genetically engineered mouse models of brain disease. 2003 Pittsburgh Conference, Orlando, FL (March 12, 2003). 

31. Serotonin and the misbehaving brain. Department of Chemistry, Duke University, Raleigh-Durham, NC (February 7, 2003). 

30. Serotonin and its reciprocal relationship with BDNF. 35th Annual Winter Conference on Brain Research, Salt Lake City, UT (January 26, 2003).

2002

top

29. Electroanalytical methods elucidate modest but biologically relevant changes in serotonin and dopamine neurotransmission. Department of Chemistry, University of North Carolina, Chapel Hill, NC (November 11, 2002).

28. Is α-synuclein giving us the run around? Department of Neurology, Columbia University Medical School, New York, NY (October 24, 2002). 

27. Serotonin and the misbehaving brain. Department of Chemistry, University of Texas at Austin, Austin, TX (October 17, 2002). 

26. Measurements in biological systems. Midwest Union of Analytical Chemistry Committee Meeting, University of Pittsburgh, Pittsburgh, PA (October, 3, 2002). 

25. Serotonin and the misbehaving brain. Department of Chemistry, University of Pittsburgh, Pittsburgh, PA (September 19, 2002). 

24. Serotonin and the misbehaving brain. Department of Chemistry, Emory University, Atlanta, GA (September 13, 2002). 

23. Serotonin and the misbehaving brain. Department of Chemistry, Georgia Institute of Technology, Atlanta, GA (September 12, 2002). 

22. The role of serotonin in MDMA-induced hyperactivity and neurotoxicity. Centers for Disease Control/National Institute for Occupational Safety and Health, Morgantown, WV (August 16, 2002). 

21. Measuring serotonin in the study of anxiety. NSF-REU Program, Department of Chemistry, James Madison University, Harrisonburg, VA (June 27, 2002). 

20. What do neuroscientists do? North Hills Junior High School, Pittsburgh, PA (May 3, 2002). 

19. Deciphering the neurochemistry of anxiety. Department of Chemistry, Olivet Nazarene University, Chicago, IL (April 1, 2002). 

18. What can measuring serotonin in vivo tell us about anxiety? 2002 Pittsburgh Conference, New Orleans, LA (March 20, 2002). 

2001

top

17. Using electrochemical techniques to analyze serotonin neurochemistry. Federation of Analytical Chemistry & Spectroscopy Societies, Detroit, MI (October 10, 2001).

16. Deciphering the neurochemistry of anxiety. Department of Chemistry, Juniata College, Juniata, PA (September 12, 2001). 

15. Deciphering the neurochemistry of anxiety. College of Science Seminar Series, Grand Canyon University, Phoenix, AZ (March 23, 2001). 

14. Deciphering the neurochemistry of anxiety. Department of Chemistry, Carlow College, Pittsburgh, PA (March 16, 2001). 

13. Deciphering the neurochemistry of anxiety. Department of Chemistry, Western Kentucky University, Bowling Green, KY (March 2, 2001). 

12. Deciphering the neurochemistry of anxiety. Department of Chemistry, Austin Peay University, Clarksville, TN (March 1, 2001). 

11. Deciphering the neurochemistry of anxiety. Central Nervous System Preclinical Research Division, Astra Zeneca, Wilmington, DE (February 15, 2001). 

2000

top

10. Deciphering the neurochemistry of anxiety. Division of Neuropathology, Johns Hopkins Medical Institutions, Baltimore, MD (December 12, 2000).

9. The neurochemistry of anxiety. Department of Chemistry, Bloomsburg University, Bloomsburg, PA (November 17, 2000). 

8. The neurochemistry of anxiety. Serotonin Club/Brain Research Bulletin Conference, New Orleans, LA (November 3, 2000). 

7. Tools to probe brain chemistry. Pennsylvania State University, Department of Bioengineering, University Park, PA (September 28, 2000). 

6. Criteria for evaluating neurotoxicity: Is 2'-NH2-MPTP a serotonergic neurotoxin? Pennsylvania State University Toxicology Forum, University Park, PA (May 10, 2000). 

5. The heterogeneous nature of the brain: Impact on etiology, diagnosis and treatment of anxiety disorders. SurroMed, Inc., Palo Alto, CA (May 8, 2000). 

4. Tools to study the brain serotonin system: Neurotoxicological approaches. St. Vincent’s College, Department of Chemistry, Latrobe, PA (March 24, 2000). 

1999

top

3. Molecular mechanisms underlying adaptation of the presynaptic serotonin system in response to decreased SERT expression: Implications for understanding the etiology and treatment of depression and anxiety. Pennsylvania State University Neuroscience Day, Hershey Medical School, Hershey, PA (May 15, 1999).

1998

top

2. Attempts to unravel differential neurochemistry in serotonin transporter knock-out mice. National Institute of Mental Health, Bethesda, MD (November 18, 1998).

1997

top

1. 2'-NH2-MPTP selectively lesions serotonin and norepinephrine nerve terminals in three species by a mechanism of action involving oxygen free radicals. National Institute on Drug Abuse Director’s Seminar Series, Baltimore, MD (June 15, 1997).


Contributed Presentations

1992  |  1993  |  1995  |  1996  |  1997  |  1998  |  1999  |  2000  |  2001  |  2002  |  2003  |  2004  |  2005  |  2006  |  2007  |  2008  |  2009  |  2010  |  2011  |  2012  |  2013  |  2014­  



top­

2014

top­  

132. Serotonin and dopamine release and reuptake by fast microdialysis. H. Yang and A. M. Andrews: 15th International Monitoring Molecules in Neuroscience Conference, University of California, Los Angeles, CA (August 3-7, 2014).

131. Serotonin transporter function in lymphoblast cell lines. B. S. Beikmann, P. R. Moya, I. D. Thomlinson, S. J. Rosenthal, D. L. Murphy, and A. M. Andrews: 11th International Society for Serotonin Research Meeting, Cape Town, South Africa (July 12, 2014).

2013

top­  

130. Perinatal escitalopram vs genetic SERT insufficiency inversely program adult serotonin states associated with anxiety. A. M. Andrews, H. Yang, H. J. O’Brien, M. F. Valdez, J. G. Hensler, D. Senturk, and S. C. Altieri: 43rd Annual Meeting of the Society for Neuroscience, San Diego, CA (November 9-13, 2013).

129. Serotonin transporter function in peripheral blood cells as a biomarker for depression treatment responsiveness. B. S. Beikmann, S. C. Altieri, P. R. Moya, Q. Wei, A. Ozcan, D. L. Murphy, A. F. Leuchter, and A. M. Andrews: 43rd Annual Meeting of the Society for Neuroscience, San Diego, CA (November 9-13, 2013).

128. A model for teaching advanced neuroscience methods to graduate students: a student-run seminar to increase practical understanding and confidence. C. R. K. Ching, T. M. Harrison, M. C. Einstein, S. L. Bonanno, A. M. Andrews, and M. S. Levine: 43rd Annual Meeting of the Society for Neuroscience, San Diego, CA (November 9-13, 2013).

127. Neurochemical comparison of two tryptophan hydroxylase inhibitors in adult and postnatal mice. T. L. Gilman, D. J. Ramos, D. Desai, S. Amin, M. Ye, M. Jung, K. E. Vrana, and A. M. Andrews: 43rd Annual Meeting of the Society for Neuroscience, San Diego, CA (November 9-13, 2013).

126. Systemic administration of the kappa opioid receptor agonist U50,488 decreases extracellular serotonin by a reuptake-independent mechanism in mice lacking the serotonin transporter. A. B. Thompson, H. Yang, and A. M. Andrews: 43rd Annual Meeting of the Society for Neuroscience, San Diego, CA (November 9-13, 2013).

125. Fast online microdialysis for serotonin and dopamine kinetics in transient neurotransmission. H. Yang, A. B. Thompson, S. C. Altieri, and A. M. Andrews: 43rd Annual Meeting of the Society for Neuroscience, San Diego, CA (November 9-13, 2013).

2012

top­

.   Early exposure to antidepressants does not recapitulate constitutive serotonin transporter deficiency. S. C. Altieri, H. Yang, H. J. O’Brien, J. G. Hensler, and A. M. Andrews: 2012 Annual Meeting of the American College of Neuropsychopharmacology, Hollywood, FL (December 4, 2012).

123. Functional common promoter and rare coding region variants in the serotonin transporter gene, SLC6A4, associated with Tourette disorder. P. R. Moya, J. R. Wendland, A. M. Andrews, L. M. Rubenstein, K. R. Timpano, G. A. Heiman, J. A. Tischfield, R. A. King, S. Ramamoorthy, F. J. McMahon, and D. L. Murphy: American Society of Genetics Annual Meeting, San Francisco, CA (November 6-10, 2012).

122. Characterizing peripheral blood cell SERT function using a fluorescent transporter substrate and flow cytometry. B. S. Beikmann, I. D. Tomlinson, S. J. Rosenthal, and A. M. Andrews: Serotonin Club Meeting, 25th Anniversary Celebration, Montpellier, France (July 10-12, 2012). 

121. Serotonin transporter deficient mice exhibit state-dependent and conditioned aversion to kappa opioid receptor activation. T. L. Gilman, K. W. Roberts, T. S. Shippenberg, C. J. Evans, and A. M. Andrews: Serotonin Club Meeting, 25th Anniversary Celebration, Montpellier, France (July 10-12, 2012). 

120. Postnatal antidepressant treatment vs constitutive SERT deficiency produce opposing changes in presynaptic 5-HT1A responses and emotion-related behavior in adolescent and adult mice. S. C. Altieri, H. Yang, H. J. O’Brien, and A. M. Andrews: Serotonin Club Meeting, 25th Anniversary Celebration, Montpellier, France (July 10-12, 2012).

2011

top

119. Optimization of conditions towards faster and more sensitive determination of monoamine neurotransmitters by HPLC. J. Zhang, Y. Liu, X. Xu, M. K. Zhao, A. Jaquins-Gerstl, A. C. Michael, A. M. Andrews, and S. G. Weber: 62st Pittsburgh Conference on Analytical Chemistry and Applied Spectroscopy, Atlanta, GA (March 15, 2011). ­

118. Optimization of capillary LC system for fast separations. Y. Liu, J. Zhang, A. C. Michael, A. M. Andrews, and S. G. Weber: 62st Pittsburgh Conference on Analytical Chemistry and Applied Spectroscopy, Atlanta, GA (March 14, 2011).

2010

­ top

117. Characterization of SERT function in mouse lymphocytes using flow cytometry. B. S. Beikmann, B. Campo-Fernandez, Y. S. Singh, S. C. Altieri, I. D. Tomlinson, S. J. Rosenthal, R. D. Blakely, and A. M. Andrews: 2010 Annual Meeting of the American College of Neuropsychopharmacology, Miami, FL (December 6, 2010).

116. GABAA receptor deficits cause HPA axis hyperactivity and antidepressant drug sensitivity reminiscent of melancholic forms of depression. Q. Shen, R. Lal, B. A. Luellen, J. C. Earnheart A. M. Andrews, and B. Lüscher: 40th Annual Meeting of the Society for Neuroscience, San Diego, CA (November 17, 2010). 

115. Predisposition to a lifetime of anxiety: Serotonin transporter and mild stress. A. J. Bressler, E. L. Unger, A. R. Lewis, S. Pajtek, and A. M. Andrews: 40th Annual Meeting of the Society for Neuroscience, San Diego, CA (November 13, 2010). 

114. Integrated microfluidic neurotransmitter-modified substrates. H. Cao, W.-S. Liao, P. S. Weiss, and A. M. Andrews: 240th ACS National Meeting & Exposition, Boston, MA (August 22-26, 2010). 

113. Spatial addressing of neurotransmitters for G-protein coupled receptors. W.-S. Liao, H. Cao, P. S. Weiss, and A. M. Andrews: 240th ACS National Meeting & Exposition, Boston, MA (August 22-26, 2010). 

112. Native peripheral lymphocytes from adult rhesus monkeys show variable serotonin uptake rates associated with 5-HTTLPR genotype. Y. S. Singh, S. C. Altieri, R. E. Ferrell, and A. M. Andrews: 2010 Serotonin Club Meeting, Montreal, Canada (July 10, 2010). 

111. Characterization of serotonin transporter function in mouse splenocytes using the novel fluorescent substrate IDT307. B. S. Beikmann, I. D. Tomlinson, S. J. Rosenthal, and A. M. Andrews: 2010 Serotonin Club Meeting, Montreal, Canada (July 10, 2010). 

110. Exploring mechanisms underlying long-term behavioral modification associated with transient postnatal serotonin transporter inhibition. S. C. Altieri, M.K. Zhao, J. G. Hensler, and A. M. Andrews: 2010 Serotonin Club Meeting, Montreal, Canada (July 10, 2010). 

109. Postnatal depletion of serotonin in mice using a novel serotonin synthesis inhibitor. T. L. Gilman, D. J. Ramos, M. K. Zhao, D. Desai, S. Amin, K. E. Vrana, and A. M. Andrews: 2010 Serotonin Club Meeting, Montreal, Canada (July 10, 2010) Invited talk and travel award. 

108. Fast separation of serotonin from microdialysates with high temperature and pressure capillary LC – electrochemical detection. X. Xu, Y. Liu, J. Zhang, M. K. Zhao, A. M. Andrews, and S. G. Weber: HPLC 2010, Boston, MA (June19-24, 2010). 

107. Capillary HPLC at elevated temperature and pressure for high‐speed neurotransmitter determinations in microdialysates. S. G. Weber, A. M. Andrews, Y. Liu, X. Xu, J. Zhang, and M. K. Zhao: 34th International Symposium on Capillary Chromatography, Riva del Garda, Italy (May 30‐June 4, 2010). 

106. Evaluation of carbon fiber microelectrode antifouling coatings for high precision and longterm serotonin detection. Y. S. Singh, L. E. Sawarynski, and A. M. Andrews: 61st Pittsburgh Conference on Analytical Chemistry and Applied Spectroscopy, Orlando, FL (February 28‐ March 5, 2010) Invited talk and travel award. 

2009

top

105. Rhesus serotonin transporter-linked promoter polymorphism is associated with differential uptake in peripheral blood lymphocytes. A. M. Andrews, L. E. Sawarynski, and Y. S. Singh: 2009 Annual Meeting of the American College of Neuropsychopharmacology, Hollywood, FL (December 6-10, 2009).

104. Investigation of materials to reduce fouling of carbon fiber microelectrodes for the detection of serotonin in vivo. L. E. Sawarynski, Y. S. Singh, B. A. Patel, and A. M. Andrews: 39th Annual Meeting of the Society for Neuroscience, Chicago, IL (October 17-21, 2009).

103. Rhesus Serotonin Transporter-Linked Promoter Polymorphism is Associated with Differential Uptake in Peripheral Blood Lymphocytes. Y. S. Singh, S. C. Altieri, and A. M. Andrews: 39th Annual Meeting of the Society for Neuroscience, Chicago, IL (October 17-21, 2009). 

102. Transcriptional regulation of BDNF in response to serotonin transporter deficiency vs. antidepressant treatment. S. C. Altieri, D. J. Vandenbergh, and A. M. Andrews: 39th Annual Meeting of the Society for Neuroscience, Chicago, IL (October 17-21, 2009). 

101. The serotonin neurotoxin 1-methyl-4-(2′-aminophenyl)-1,2,3,6-tetrahydropyridine does not alter anxiety-related behavior or impair acquisition of spatial navigation in the Lashley III maze. A. J. Bressler, S. A. Belegundu, M. K. Zhao, A. R. Lewis and A. M. Andrews: 39th Annual Meeting of the Society for Neuroscience, Chicago, IL (October 17-21, 2009). 

100. Is neophobia or behavioral inhibition related to anxiety-related behavior in mice? C. M. Ragan, A. J. Bressler, S. A. Belegundu, A. R. Lewis, B. C. Jones, N. Vasudevan, A. M. Andrews, and S. A. Cavigelli: 39th Annual Meeting of the Society for Neuroscience, Chicago, IL (October 17-21, 2009). 

99. Segregating contextual versus social neophobia in two strains of BXD recombinant inbred mice. A. J. Bressler, C. M. Ragan, S. A. Belegundu, A. R. Lewis, B. C. Jones, N. Vasudevan, S. A Cavigelli, and A. M. Andrews: 39th Annual Meeting of the Society for Neuroscience, Chicago, IL (October 17-21, 2009). 

98. 5-Hydroxytryptophan-functionalized and patterned surfaces for selective binding of membrane-associated serotonin receptors. A. Vaish, M. J. Shuster, P. S. Weiss, and A. M. Andrews: 2009 Biomedical Engineering Society Annual Meeting, Pittsburgh, PA (October 7-10, 2009). 

97. 5-Hydroxytryptophan-functionalized self-assembled mono-layers capture native membrane-associated serotonin receptors. A. Vaish, M. J. Shuster, P. S. Weiss, and A. M. Andrews: 237th ACS National Meeting & Exposition, Salt Lake City, UT (March 22, 2009). 

96. Measuring serotonin transporter function in rhesus peripheral blood lymphocytes using boron-doped diamond electrodes. Y. S. Singh, B. S. Beikmann, L. E. Sawarynski, B. A. Patel, and A. M. Andrews: 237th ACS National Meeting & Exposition, Salt Lake City, UT (March 22, 2009). 

2008

top

95. BDNF transcript variants and anxiety behavior in SERT-deficient mice after chronic antidepressant treatment. S. C. Altieri, J. P. Gyekis, B. B. Osborne, D. J. Vandenbergh, and A. M. Andrews: 38th Annual Meeting of the Society for Neuroscience, Washington, DC (November 15-19, 2008).

94. Serotonin uptake in rhesus peripheral blood mononuclear cells using boron-doped diamond electrodes and chronoamperometry. Y. S. Singh, B. A. Patel, L. E. Sawarynski, and A. M. Andrews: 38th Annual Meeting of the Society for Neuroscience, Washington, DC (November 15-19, 2008). 

93. Strain 11 B×D recombinant inbred mice display a complex phenotype characterized by increased anxiety-related behavior and hypolocomotion compared to stain 31. S. A. Belegundu, A. J. Bressler, A. R. Lewis, B. C. Jones, N. Vasudevan, and A. M. Andrews: 38th Annual Meeting of the Society for Neuroscience, Washington, DC (November 15-19, 2008). 

92. Serotonin transporter function and regulation in lymphoblasts from mice with constitutive reductions in SERT expression. B. S. Beikmann, A. J. Bressler, and A. M. Andrews: 38th Annual Meeting of the Society for Neuroscience, Washington, DC (November 15-19, 2008). 

91. Transcriptional control of BDNF in response to stress and constitutive reductions in SERT expression. B. B. Osborne, S. C. Altieri, M. E. Szapacs, D. J. Vandenbergh, and A. M. Andrews: 38th Annual Meeting of the Society for Neuroscience, Washington, DC (November 15-19, 2008). 

90. Mild periadolescent stress potentiates increases in anxiety-like behavior associated with reduced SERT expression in mice. A. R. Lewis, A. J. Bressler, and A. M. Andrews: 38th Annual Meeting of the Society for Neuroscience, Washington, DC (November 15-19, 2008). 

89. Effects of aging on route learning in the Lashley maze in mice with constitutive reductions in BDNF expression. A. J. Bressler, A. R. Lewis, S. A. Belegundu, B. S. Beikmann, L. Tessarrollo, D. A. Blizard, and A. M Andrews: 38th Annual Meeting of the Society for Neuroscience, Washington, DC (November 15-19, 2008). 

88. The Neurochip: A biologically inspired nanosurface for small molecule capture of biomolecule binding partners. A. Vaish, M. J. Shuster, P. S. Weiss, and A. M. Andrews: Biomedical Engineering Society Annual Fall Meeting, St. Louis, MO (October 2, 2008). 

87.  Improved route learning in aging mice with constitutive reductions in brain-derived neurotrophic factor. A. J. Bressler, T. N. Chrzanowski, A. R. Lewis, S. A. Belegundu, B. S. Beikmann, L. Tessarrollo, B. A. Luellen, D. A. Blizard, A. M. Andrews: Serotonin Club Meeting, Oxford, England (July 18, 2008).

86.  Effects of subchronic restraint stress on brain-derived neurotrophic factor in serotonin transporter deficient mice. S. C. Altieri, M. E. Szapacs, B. B. Osborne, D. J. Vandenbergh, A. M. Andrews: Serotonin Club Meeting, Oxford, England (July 18, 2008).

85. Small molecule functionalized capture materials for functionally-directed brain proteomics and neurotransmitter sensing. A. Vaish, M. J. Shuster, P. S. Weiss and A. M. Andrews: 59th Pittsburgh Conference on Analytical Chemistry and Applied Spectroscopy, New Orleans, LA (March 1-7, 2008). 

84. Using high-speed chronoamperometry to determine native serotonin transporter function in human lymphoblasts. A. J. Bressler, T. N. Chrzanowski, R. Ren-Patterson, D. L. Murphy and A. M. Andrews: 59th Pittsburgh Conference on Analytical Chemistry and Applied Spectroscopy, New Orleans, LA (March 3, 2008). 

2007

top

83. Deficits in gamma2 subunit containing GABA-A receptors affect neuronal maturation independently of changes in BDNF and serotonergic transmission. N. Sahir, B. A. Luellen, J. C. Earnheart, A. M. Andrews and B. Luscher: 37th Annual Meeting of the Society for Neuroscience, San Diego, CA (November 3-7, 2007).

82. Anxiety-related behavior, locomotor activity and route learning in aging APP/PS1 transgenic mice. M. M. Maxon, T. N. Chrzanowski, A. J. Bressler, A. R. Lewis, D. A. Blizard, A. M. Andrews: 37th Annual Meeting of the Society for Neuroscience, San Diego, CA (November 3, 2007). 

81. Marble burying in aging serotonin transporter (SERT) deficient mice. C. A. Lieu, A. J. Bressler, A. R. Lewis, R. J. Milner, A. M. Andrews: 37th Annual Meeting of the Society for Neuroscience, San Diego, CA (November 3, 2007). 

80. Recombinant inbred mouse strains as tools to identify new genes underlying anxiety. A. R. Lewis, A. J. Bressler, B. C. Jones, S. A. Cavagelli, N. Vasudevan and A. M. Andrews: 37th Annual Meeting of the Society for Neuroscience, San Diego, CA (November 7, 2007). 

79. Aging mice with reduced BDNF expression show improved learning and memory in a low stress route learning task. A. J. Bressler, T. N. Chrzanowski, A. R. Lewis, L. Tessarrollo, D. A. Blizard and A. M. Andrews: 37th Annual Meeting of the Society for Neuroscience, San Diego, CA (November 3, 2007). 

78. Serotonin release and reuptake using in vivo fast cyclic voltammetry in serotonin transporter deficient mice. Y. S. Singh, B. A. Patel, A. J. Bressler, G. M. Swain and A. M. Andrews: 37th Annual Meeting of the Society for Neuroscience, San Diego, CA (November 7, 2007). 

77. Serotonin uptake rates in synaptosomes using boron-doped diamond electrodes. Y. S. Singh, B. A. Patel, A. J. Bressler, G. M. Swain and A. M. Andrews: 37th Annual Meeting of the Society for Neuroscience, San Diego, CA (November 7, 2007). 

76. Hippocampal cellular proliferation is decreased in aging SERT null mutant mice. M. K. Zhao and A. M. Andrews: 37th Annual Meeting of the Society for Neuroscience, San Diego, CA (November 7, 2007). 

75. Behavioral inhibition in a novel physical environment is unrelated to social investigation. N. Vasudevan, C. E. Kovacsics, S. A. Cavigelli, A. J. Bressler, A. M. Andrews and B. C. Jones: 11th Annual Society of Behavioral Endocrinology Meeting, Pacific Grove, CA (June 22, 2007). 

2006

top

74. High-speed chronoamperometric determination of serotonin transporter function in human lymphoblasts. Y. Singh, A. J. Bressler, R. Ren-Patterson, D. L. Murphy and A. M. Andrews: 36th Annual Meeting of the Society for Neuroscience, Atlanta, GA (October 17, 2006).

73. Mice lacking the serotonin transporter maintain robust increases in anxiety-related behavior and show reduced hippocampal neurogenesis into old age. S. Pajtek, B. A. Luellen and A. M. Andrews: 36th Annual Meeting of the Society for Neuroscience, Atlanta, GA (October 17, 2006).

72. Single molecule placement of serotonin in self-assembled monolayers allows selective recognition by antibodies and native transmembrane receptors. P. S. Weiss, M. J. Shuster, A. U. Vaish and A. M. Andrews: 36th Annual Meeting of the Society for Neuroscience, Atlanta, GA (October 14, 2006). 

71. The neurochip: An advanced nanosurface for small molecule capture of biomolecule binding partners. M. J. Shuster, A. U. Vaish, T. J. Mullen, P. S. Weiss and A. M. Andrews: CrossOver 2006, University Park, PA (October 12, 2006). 

70. A physical model of axonal damage due to oxidative stress. P. S. Weiss, A. E. Counterman, T. G. D’Onofrio and A. M. Andrews: 10th International Conference on Alzheimer’s Disease and Related Disorders, Madrid, Spain (July 18, 2006).

69. The neurotoxin 2'-NH2-MPTP models degeneration of serotonin axons and alterations in hippocampal BDNF occurring in Alzheimer's disease. A. M. Andrews, C. K. Materese, M. E. Szapacs and B. A. Luellen: 10th International Conference on Alzheimer’s Disease and Related Disorders, Madrid, Spain (July 18, 2006). 

68. Single molecule placement of small molecule probes in SAMs allows selective recognition by large biomolecule binding partners. A. M. Andrews, A. U. Vaish, M. J. Shuster and P. S. Weiss: Foundations of Nanoscience (FNANO 06) Self-Assembled Architectures and Devices, Snowbird, UT (April 25, 2006). 

67. The neurochip: An advanced nanomaterial for small molecule capture of biomolecule binding partners. A. U. Vaish, M. J. Shuster, P. S. Weiss, M. V. Pishko and A. M. Andrews: Materials Research Society, Spring 2006 Meeting, San Francisco, CA (April 18, 2006). 

66. Nanostructured neurotransmitter-derivatized surfaces for biosensor development. A. U. Vaish, M. J. Shuster, M. V. Pishko, P. S. Weiss and A. M. Andrews: Gordon Conference on Biosensors, Ventura, CA (February 28, 2006). 

2005

top

65. Nanostructured neurotransmitter-derivatized surfaces for biosensor development. A. M. Andrews, M. E. Szapacs, A. S. Cans, A. U. Vaish, J. L. Han, M. E. Anderson and P. S. Weiss: PacifiChem 2005, Honolulu, HI (December 19, 2005).

64. Serotonin transport measured using carbon fiber microelectrodes and chronoamperometry yields new insights into brain function. A. M. Andrews and X. A. Perez: PacifiChem 2005, Honolulu, HI (December 17, 2005). 

63. Altered serotonin synthesis, turnover, and dynamic regulation in multiple brain regions of mice lacking the serotonin transporter. D.-T. Kim, T. J. Tolliver, S. Huang, B. J. Martin, A. M. Andrews, A. Holmes, K.-P Lesch and D. L. Murphy: 35th Annual Meeting of the Society for Neuroscience, Washington, DC (November 13, 2005).

62. Reduced BDNF expression is associated with potentiated loss of serotonergic innervation in the hippocampus of aging mice. B. A. Luellen, L. E. Killingbeck, L. M. Schneider and A. M. Andrews: 35th Annual Meeting of the Society for Neuroscience, Washington, DC (November 13, 2005). 

61. Methods to evaluate serotonin neurotransmission and BDNF in aging and degenerative and psychiatric diseases. A. M. Andrews: 35th Annual Meeting of the Society for Neuroscience, Washington, DC (November 14, 2005). 

60. MDMA-induced dopamine release does not stimulate locomotor activity in SERT knockout mice: Role of extracellular serotonin and the 5-HT1B receptor. T. A. Mathews, E. L.Unger, D. E. Fedele, K.-P. Lesch, D. L. Murphy, A. M. Andrews: New Perspectives in Neurotransmitter Transporter Biology, 15th Neuropharmacology Conference, Washington, DC (November 10, 2005). 

59. Chronoamperometry versus radiochemical methods for determining serotonin uptake: Why such discrepancies? X. A. Perez, L. E. Killingbeck, A. M. Andrews: New Perspectives in Neurotransmitter Transporter Biology, 15th Neuropharmacology Conference, Washington, DC (November 9, 2005). 

58. The neurochip: An advanced nanomaterial for the development of novel biosensors and functionally-directed proteomics. A. M. Andrews: ChinaNANO 2005, Bejing, China (June 9, 2005).

2004

top

57. BDNF mRNA and protein levels in SERT knockout mice as a function of age and cellular and environmental stress factors. A. P. McGraw, M. E. Szapacs, D. J. Vandenbergh and A. M. Andrews: 34th Annual Meeting of the Society for Neuroscience, San Diego, CA (October 26, 2004).

56. Differential effects of MDMA and METH on motor activity and striatal 5-HT and DA release in SERT knockout mice. A. M. Andrews, E. L. Unger and T. A. Mathews: 34th Annual Meeting of the Society for Neuroscience, San Diego, CA (October 26, 2004). 

55. Chronoamperometric determination of serotonin transporter function in synaptosomes: Comparison with traditional radiochemical methods. X. A. Perez and A. M. Andrews: 34th Annual Meeting of the Society for Neuroscience, San Diego, CA (October 25, 2004). 

54. Serotonin transporter knockout mice exhibit gene dose-dependant variations in extracellular serotonin and extraction fraction in hippocampus. L. E. Killingbeck and A. M. Andrews: 34th Annual Meeting of the Society for Neuroscience, San Diego, CA (October 24, 2004). 

53. 2'-NH2-MPTP-induced depletions in serotonin and norepinephrine increase BDNF levels and compromise the structural integrity of neurons. B. A. Luellen, M. E. Szapacs, A. P. McGraw, A. L. Numis and A. M. Andrews: 34th Annual Meeting of the Society for Neuroscience, San Diego, CA (October 24, 2004). 

52. Late onset loss of hippocampal 5-HT and NE is accompanied by an increase in BDNF protein expression in mice co-expressing mutant APP and PS1. M. E. Szapacs, A. L. Numis and A. M. Andrews: The 9th International Conference of Alzheimer’s Disease and Related Disorders, Philadelphia, PA (2004). 

51. Constitutive reductions in SERT expression alter age-dependent changes in serotonin innervation patterns. B. A. Luellen, E. L. Unger, W. E. Lyons, M. E. Blue, L. A. Mamounas and A. M. Andrews: 4th Meeting of the Federation of European Pharmacological Societies, Porto, Portugal (2004). 

50. The role of increased extracellular serotonin in age-related changes in serotonergic and catecholaminergic forebrain innervation and astrocytic response. B. A. Luellen, W. E. Lyons, M. E. Blue, L. A. Mamounas and A. M. Andrews: Serotonin Satellite Symposium of the 4th Meeting of the Federation of European Pharmacological Societies, Porto, Portugal (2004). 

49. The role of mitogen activated protein kinase pathways in age-related neuroprotection in serotonin transporter knockout mice. J. E. Cavanaugh, T. Smith, E. L. Unger, B. A. Luellen, A. M. Andrews and J. M. Lakoski: Serotonin Satellite Symposium of the 4th Meeting of the Federation of European Pharmacological Societies, Porto, Portugal (2004). 

48. Chronoamperometric determination of serotonin transporter function in synaptosomes: Comparison with traditional radiochemical methods. X. A. Perez, C. M. Squillante and A. M. Andrews: 55th Pittsburgh Conference on Analytical Chemistry and Applied Spectroscopy, Chicago, IL (2004).

2003

top

47. Quantitative microdialysis in BDNF knockout mice. L. A. Killingbeck, T. A. Mathews, W. E. Lyons, L. A. Mamounas and A. M. Andrews: 33rd Annual Meeting of the Society for Neuroscience, New Orleans, LA (2003).

46. Serotonin may be necessary for the astrocytic response to neuronal injury: Studies using 2'-NH2-MPTP. B. A. Luellen, A. L. Numis, D. L. Murphy, D. B. Miller, J. P. O’Callaghan and A. M. Andrews: 33rd Annual Meeting of the Society for Neuroscience, New Orleans, LA (2003).

45. Role of the vesicular monoamine transporter in the neurotoxic effects of 2'-NH2-MPTP in mice and rats. A. L. Numis and A. M. Andrews: 33rd Annual Meeting of the Society for Neuroscience, New Orleans, LA (2003). 

44. BDNF levels in SERT knockout mice and their responsiveness to stress. M. E. Szapacs, A. P. McGraw, K. J. Sowinski and A. M. Andrews: 33rd Annual Meeting of the Society for Neuroscience, New Orleans, LA (2003). 

43. Basal extracellular and METH-induced striatal DA levels in SERT knockout mice. T. A. Mathews, E. L. Unger, A. C. Chisnell and A. M. Andrews: 33rd Annual Meeting of the Society for Neuroscience, New Orleans, LA (2003). 

42. Serotonin and the fountain of youth: An examination of age-related serotonergic axon preservation versus serotonin levels in the forebrain of serotonin transporter knockout mice. A. L. Numis, E. L. Unger, B. A. Luellen, and A. M. Andrews: 2003 Undergraduate Exhibition, Pennsylvania State University, University Park, PA (2003). 

41. Synthesis of serotonin or dopamine coupled to solid support permitting interaction of all available functional groups. M. E. Szapacs, E. D. Horowitz, R. S. Bridges, P. C. Bevilacqua, R. L. Funk and A. M. Andrews: 54th Pittsburgh Conference on Analytical Chemistry and Applied Spectroscopy, Orlando, FL (2003). 

40. Electroanalytical methods elucidate the role of mutant α-synuclein in dopamine neurotransmission and Parkinson’s disease. X. A. Perez, T. A. Mathews, E. L. Unger, D. K. Reichenbach, M. K. Lee and A. M. Andrews: 54th Pittsburgh Conference on Analytical Chemistry and Applied Spectroscopy, Orlando, FL (2003). 

39. Decreased serotonin transporter expression prevents age-related serotonergic fiber loss in the forebrain. E. L. Unger, B. A. Luellen, O. Lee, W. E. Lyons, M. E. Blue, L. A. Mamounas and A. M. Andrews: 35th Annual Winter Conference on Brain Research, Salt Lake City, UT (2003). 

2002

top

38. Basal extracellular and METH-induced striatal DA levels in SERT knockout mice. T. A. Mathews, E. L. Unger, A. C. Chisnell and A. M. Andrews: 32nd Annual Meeting of the Society for Neuroscience, Orlando, FL (2002).

37. The effect of serotonin axon degeneration on functional 5-HT neurotransmission and behavior. M. D. Aponte, D. K. Reichenbach, B. A. Luellen, T. A. Mathews and A. M. Andrews: 32nd Annual Meeting of the Society for Neuroscience, Orlando, FL (2002). 

36. Decreased serotonin transporter expression prevents age-related serotonergic fiber loss in the forebrain. E. L. Unger, B. A. Luellen, O. Lee, W. E. Lyons, M. E. Blue, L. A. Mamounas and A. M. Andrews: 32nd Annual Meeting of Society for Neuroscience, Orlando, FL (2002). 

35. Preclinical motor abnormalities in A53T α-synuclein transgenic mice are age-dependent. D. K. Reichenbach, E. L. Unger, W. X. Li, D. Eve, M. K. Lee and A. M. Andrews: 32nd Annual Meeting of the Society for Neuroscience, Orlando, FL (2002). 

34. Degeneration of serotonin axons is accompanied by decreased 5-HT and increased BDNF in a transgenic mouse model of AD. A. L. Numis, M. E. Szapacs, M. K. Lee and A. M. Andrews: 32nd Annual Meeting of the Society for Neuroscience, Orlando, FL (2002). 

33. RT-PCR analysis of BDNF mRNA in SERT knockout mice versus mice chronically treated with 5-HT reuptake inhibitors. K. J. Sowinski, M. E. Szapacs, C. M. McCann, E. L. Unger, D. J. Vandenbergh and A. M. Andrews: 32nd Annual Meeting of the Society for Neuroscience, Orlando, FL (2002). 

32. Electroanalytical methodology elucidates changes in synaptic 5-HT caused by intermediate reductions in SERT expression. A. M. Andrews, T. A. Mathews and X. A. Perez: 32nd Annual Meeting of the Society for Neuroscience, Orlando, FL (2002). 

31. Regionally selective and progressive degeneration of the 5-HT system in a transgenic mouse model of AD. M. J. Yoo, W. Stirling, O. Lee, W. X. Li, M. E. Blue, A. M. Andrews, W. E. Lyons, L. A. Mamounas and M. K. Lee: World Alzheimer’s Congress, Stockholm, Sweden (2002). 

30. A53T α-synuclein transgenic mice show preclinical motor abnormalities that precede the development of fatal motoric dysfunction. E. L. Unger, D. K. Reichenbach, M. K. Lee and A. M. Andrews: World Alzheimer’s Congress, Stockholm, Sweden (2002). 

29. Decreased serotonin transporter expression prevents age-related serotonergic fiber loss in forebrain. E. L. Unger, O. Lee, W. E. Lyons, M. E. Blue, L. A. Mamounas and A. M. Andrews: World Alzheimer’s Congress, Stockholm, Sweden (2002). 

28. Adaptations in dopamine neurochemistry in SERT knockout mice by microdialysis and chronoamperometry. X. A. Perez, T. A. Mathews, A. C. Chisnell and A. M. Andrews: American Chemical Society 224th National Meeting, Boston, MA (2002). 

27. Synthesis of serotonin or dopamine coupled to solid support permitting interaction of all available functional groups. M. E. Szapacs, E. D. Horowitz, R. S. Bridges, P. C. Bevilacqua, R. L. Funk and A. M. Andrews: Gordon Research Conference on Bioanalytical Sensors, Ventura, CA (2002). 

2001

top

26. Molecular mechanisms of cocaine reward: Combined dopamine and serotonin transporter knockouts eliminate cocaine place preference. I. Sora, F. S. Hall, A. M. Andrews, M. Itokawa, X.-F. Li, H.-B Wei, H. Yamamoto, T. Yamamoto, K. Ikeda, C. Wichems, K.-P. Lesch, D. L. Murphy and G. R. Uhl: 31st Annual Meeting of the Society for Neuroscience, San Diego, CA (2001).

25. Expression of human α-synuclein harboring the A53T, but not A30P, mutation leads to neurodegeneration in transgenic mice. M. K. Lee, W. Sterling, D. Eve, Y. Xu,, A. Mandir, T. Dawson V. Dawson A. M. Andrews and D. L. Price: 31st Annual Meeting of the Society for Neuroscience, San Diego, CA (2001). 

24. Cerebral amyloid deposition in APP/PS1 double transgenic mice is associated with induction of dystrophic serotonergic fibers. L. A. Mamounas, W. E. Lyons, O. Lee, W.-X. Li, W. Sterling, A. M. Andrews, E. L. Unger, A. C. Chisnell and M. K. Lee: 31st Annual Meeting of the Society for Neuroscience, San Diego, CA (2001). 

23. 5-HT, NE and BDNF levels in mice with pharmacologically or genetically-induced decreases in 5-HT uptake. M. E. Szapacs, C. M. McCann, E. L. Unger and A. M. Andrews: 31st Annual Meeting of the Society for Neuroscience, San Diego, CA (2001). 

22. Dopamine uptake in serotonin transporter knockout mice by chronoamperometry. X. A. Perez and A. M. Andrews: 31st Annual Meeting of the Society for Neuroscience, San Diego, CA (2001). 

21. Quantitative microdialysis for serotonin in BDNF knockout mice. T. A. Mathews, D. E. Fedele, L. A. Mamounas, W. E. Lyons and A. M. Andrews: 31st Annual Meeting of the Society for Neuroscience, San Diego, CA (2001).

20. Effects of 2'-NH2-MPTP in VMAT2 knockout mice. A. C. Chisnell, E. L. Unger, B. A. Fierst, D. L. Sheridan and A. M. Andrews: 31st Annual Meeting of the Society for Neuroscience, San Diego, CA (2001). 

19. Age-related changes in 5-HT immunocytochemistry in SERT knockout mice. A. M. Andrews, E. L. Unger, A. C. Chisnell, W. E. Lyons and L. A. Mamounas: 31st Annual Meeting of the Society for Neuroscience, San Diego, CA (2001). 

18. Quantitative microdialysis for serotonin in striatum and frontal cortex of genetically altered mice. D. E. Fedele, T. A. Mathews, L. A. Mamounas, W. E. Lyons and A. M. Andrews: Proceedings of the 9th International Conference on In Vivo Methods, Dublin, Ireland (2001). 

2000

top

17. BDNF regulation of serotonin functioning and plasticity. L. A. Mamounas, C. A. Altar, A. M. Andrews and W. E. Lyons: Serotonin Club/Brain Research Bulletin Conference, New Orleans, LA (2000).

16. 5-HT reuptake in SERT knockout mice by chronoamperometry. X. A. Perez and A. M. Andrews: Serotonin Club/Brain Research Bulletin Conference, New Orleans, LA (2000).

15. Mechanisms mediating the increased anxiety-like and excess responses to stress in mice lacking the serotonin transporter. C. H. Wichems, Q. Li, A. Holmes, J. N. Crawley, O. Tjurmina, D. Goldstein, A. M. Andrews, K.-P. Lesch and D. L. Murphy: 30th Annual Meeting of the Society for Neuroscience, New Orleans, LA (2000). 

14. Binge-type behavior and brain serotonin. R. L. Corwin, S. F. Wagner, H. B. Rice and A. M. Andrews: 30th Annual Meeting of Society for Neuroscience, New Orleans, LA (2000). 

13. Effects of serotonin transporter inactivation on extracellular 5-HT levels, in vivo microdialysis recovery, and MDMA-induced release of serotonin and dopamine in mouse striatum. T. A. Mathews, D. E. Fedele, E. L. Unger, K.-P. Lesch, D. L. Murphy and A. M. Andrews: 30th Annual Meeting of the Society for Neuroscience, New Orleans, LA (2000).

1999

top

12. The effects of PCPA on monoamine neurotransmitter levels in mice with a disruption of the serotonin transporter gene. D. L. Sheridan, C. H. Wichems, D. L. Murphy, and A. M. Andrews: 29th Annual Meeting of the Society for Neuroscience, Miami, FL (1999).

11. A microdialysis study of the effects of genetic inactivation of the serotonin transporter gene on baseline and K+-stimulated extracellular serotonin concentrations in mouse striatum. D. E. Fedele and A. M. Andrews: Proceedings of the 8th International Conference on In Vivo Methods, Stony Brook, NY (1999).

1998

top

10. A microdialysis study of the effects of high K+ and paroxetine on extracellular serotonin concentrations in serotonin transporter knock-out mice. A. M. Andrews, C. H. Wichems, Q. Li, A. Heils, K.-P. Lesch and D. L. Murphy: 28th Annual Meeting of the Society for Neuroscience, Los Angeles, CA (1998).

1997

top

9. The effects of MDMA on monoamine neurotransmitter levels and core temperature in mice with a disrupted serotonin transporter. A. M. Andrews, C. H. Wichems, D. Bengel, K.-P. Lesch and D. L. Murphy: 27th Annual Meeting of the Society for Neuroscience, New Orleans, LA (1997).

8. 2'-NH2-MPTP selectively depletes cortical and hippocampal 5-HT and NE in the rat: A comparison with 2'-CH3-MPTP. A. M. Andrews, P. Mazzola-Pomietto and D. L. Murphy: 1997 Joint Meeting of the International Society for Neurochemistry and the American Society for Neurochemistry, Boston, MA (1997). 

1996

top

7. Targeted disruption of the murine serotonin transporter gene. D. Bengel, D. L. Murphy, A. M. Andrews, D. Feltner, C. H. Wichems, M. Seemann, A. Heils, A. Grinberg, H. Westphal and K.-P. Lesch: 1996 Annual Meeting of the American College of Neuropsychopharmacology, San Juan, PR (1996). 

6. 2'-NH2-MPTP selectively depletes cortical and hippocampal 5-HT and NE in the rat: A cross-species comparison versus MPTP and 2'-CH3-MPTP. A. M. Andrews, P. Mazzola-Pomietto and D. L. Murphy: 1996 Annual Meeting of the American College of Neuropsychopharmacology, San Juan, PR (1996).

5. Transgenic mice with high levels of superoxide dismutase activity are protected from the neurotoxicity of 2'-NH2-MPTP on serotonin and norepinephrine nerve terminals. A. M. Andrews, B. Ladenheim, J. L. Cadet and D. L. Murphy: 26th Annual Meeting of the Society for Neuroscience, Washington, DC (1996). 

1995

top

4. Acute neurotoxicity of 2'-NH2-MPTP: Changes in regional serotonin, 5-HIAA, norepinephrine, dopamine and GFAP levels in Swiss Webster mice. A. M. Andrews, D. B. Miller, J. P. O'Callaghan and D. L. Murphy: 25th Annual Meeting of the Society for Neuroscience, San Diego, CA (1995).

1993

top

3. 2'-NH2-MPTP in Swiss Webster mice: Evidence for long term depletions in cortical and hippocampal serotonin and norepinephrine and differential protection by selective uptake inhibitors or monoamine oxidase inhibitors. A. M. Andrews and D. L. Murphy: 1993 Annual Meeting of the American College of Neuropsychopharmacology, Honolulu, HA (1993).

2. Uptake inhibitors selectively attenuate depletions in cortical and hippocampal serotonin and norepinephrine caused by 2'-NH2-MPTP in two strains of mice. A. M. Andrews and D. L. Murphy: 23rd Annual Meeting of the Society for Neuroscience, Washington, DC (1993).

1992

top

1. 2'-Amino substituted MPTP depletes brain serotonin and norepinephrine without affecting dopamine in C57BL/6 mice. A. M. Andrews, N. A. Garrick and D. L. Murphy: 22nd Annual Meeting of the Society for Neuroscience, Anaheim, CA (1992).

­ 





Neuroscience Research Building  •  635 Charles E. Young Dr. South  •  University of California, Los Angeles  •  Los Angeles, CA 90095  •  Log In